Invanz and Humalog drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Invanz (ertapenem sodium) and Humalog (insulin lispro recombinant). Common drug interactions include head discomfort among females and pancytopenia among males.

The phase IV clinical study analyzes what interactions people have when they take Invanz and Humalog. It is created by eHealthMe based on reports of 31 people who take the same drugs from the FDA, and is updated regularly.

What is Invanz?

Invanz has active ingredients of ertapenem sodium. It is often used in urinary tract infection. eHealthMe is studying from 3,961 Invanz users. Check the latest studies of Invanz.

What is Humalog?

Humalog has active ingredients of insulin lispro recombinant. It is often used in diabetes. eHealthMe is studying from 137,127 Humalog users. Check the latest studies of Humalog.



On Jul, 12, 2026

31 people who take Invanz and Humalog together, and have interactions are studied.

Invanz and Humalog drug interactions.

What are the common drug interactions of Invanz and Humalog, by gender? *:

female:

  1. Head discomfort
  2. Hypercalcaemia (elevated calcium (ca+) level in the blood)
  3. Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)
  4. Hypertension (high blood pressure)
  5. Hypokalaemia (low potassium)
  6. Nephrogenic anaemia (anaemia due to kidney disease)
  7. Renal failure (kidney dysfunction)
  8. Renal injury (kidney injury)
  9. Sepsis (a severe blood infection that can lead to organ failure and death)
  10. Thrombocytopenic purpura (a bleeding disorder in which the immune system destroys platelets)

male:

  1. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  2. Decubitus ulcer (a chronic ulcer of the skin caused by prolonged pressure on it)
  3. Hypotension (abnormally low blood pressure)
  4. Pyrexia (fever)
  5. Sepsis (a severe blood infection that can lead to organ failure and death)
  6. Neutropenia (an abnormally low number of neutrophils)
  7. Adverse reaction
  8. Aggression
  9. Arthralgia (joint pain)
  10. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)

What are the common drug interactions of Invanz and Humalog, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  2. Anger
  3. Dreamy state
  4. Hallucination, auditory (perceiving sounds without auditory stimulus)
  5. Blood pressure systolic increased
  6. Dyspepsia (indigestion)
  7. Vertigo

50-59:

  1. Staphylococcal infection (an infection with staphylococcus bacteria)
  2. Surgery
  3. Urinary tract infection fungal
  4. Ventricular tachycardia (rapid heartbeat that originates in one of the lower chambers (the ventricles) of the heart)
  5. Confusional state
  6. Bacteraemia (presence of bacteria in the blood)
  7. Acute respiratory failure
  8. Blood glucose decreased
  9. Cardiomyopathy (weakening of the heart muscle)
  10. Haematocrit decreased

60+:

  1. Anaemia (lack of blood)
  2. Cutaneous vasculitis (an inflammatory process affecting the vessel wall that leads to its damage)
  3. Arthralgia (joint pain)
  4. Asthenia (weakness)
  5. B-cell lymphoma (blood cancer affecting b cells)
  6. Blood glucose increased
  7. Cellulitis (infection under the skin)
  8. Chronic obstructive pulmonary disease (a progressive disease that makes it hard to breathe)
  9. Clostridium test positive
  10. Diabetic ulcer

What are the existing conditions these people have? *

  1. Pain: 8 people, 25.81%
  2. Type 2 Diabetes: 5 people, 16.13%
  3. Constipation: 5 people, 16.13%
  4. Infection: 4 people, 12.90%
  5. Dyslipidaemia (abnormal amount of lipids): 4 people, 12.90%
  6. Anaemia (lack of blood): 4 people, 12.90%
  7. Stress And Anxiety: 2 people, 6.45%
  8. Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 6.45%
  9. Multiple Myeloma (cancer of the plasma cells): 2 people, 6.45%
  10. Migraine (headache): 2 people, 6.45%

* Approximation only. Some reports may have incomplete information.

Do you take Invanz and Humalog?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Invanz and Humalog:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Invanz:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Humalog:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Invanz and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Humalog and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on ertapenem sodium and insulin lispro recombinant (the active ingredients of Invanz and Humalog, respectively), and Invanz and Humalog (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: